INNOGEN-B Shares Climb Over 3% in Morning Session as Esupaglutide Alpha Added to Qilu Insurance List

Stock News04-02

INNOGEN-B (02591) rose more than 3% during morning trading. At the time of writing, the stock was up 2.94% to HK$22.22, with a turnover of HK$1.966 million. On April 1, INNOGEN announced via its official social media account that Esupaglutide Alpha (Yinuoqing®) has been officially included in the specific drug list for online outpatient services under the "Qilu Insurance" program, for the treatment of adult patients with type 2 diabetes. Clinical studies have shown that Esupaglutide Alpha, as a new-generation GLP-1 drug, demonstrates effective glucose-lowering results in the treatment of type 2 diabetes in adults. Additionally, positive data has been observed in weight-loss related clinical studies conducted in China and Australia. As a supplement to the flexible use of drugs listed in the National Reimbursement Drug List, this initiative represents the first and currently only practice in China combining a Class 1 GLP-1 innovative drug with commercial insurance online outpatient services. This move marks a significant step for INNOGEN in enhancing the accessibility of its innovative drug Yinuoqing® and supporting chronic disease management.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147586009?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147586009","market":"other","top_or_hot":-1,"title":"INNOGEN-B Shares Climb Over 3% in Morning Session as Esupaglutide Alpha Added to Qilu Insurance List","media":"Stock News","content":"<p>INNOGEN-B (02591) rose more than 3% during morning trading. At the time of writing, the stock was up 2.94% to HK$22.22, with a turnover of HK$1.966 million. On April 1, INNOGEN announced via its official social media account that Esupaglutide Alpha (Yinuoqing®) has been officially included in the specific drug list for online outpatient services under the \"Qilu Insurance\" program, for the treatment of adult patients with type 2 diabetes. Clinical studies have shown that Esupaglutide Alpha, as a new-generation GLP-1 drug, demonstrates effective glucose-lowering results in the treatment of type 2 diabetes in adults. Additionally, positive data has been observed in weight-loss related clinical studies conducted in China and Australia. As a supplement to the flexible use of drugs listed in the National Reimbursement Drug List, this initiative represents the first and currently only practice in China combining a Class 1 GLP-1 innovative drug with commercial insurance online outpatient services. This move marks a significant step for INNOGEN in enhancing the accessibility of its innovative drug Yinuoqing® and supporting chronic disease management.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B Shares Climb Over 3% in Morning Session as Esupaglutide Alpha Added to Qilu Insurance List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B Shares Climb Over 3% in Morning Session as Esupaglutide Alpha Added to Qilu Insurance List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-02 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) rose more than 3% during morning trading. At the time of writing, the stock was up 2.94% to HK$22.22, with a turnover of HK$1.966 million. On April 1, INNOGEN announced via its official social media account that Esupaglutide Alpha (Yinuoqing®) has been officially included in the specific drug list for online outpatient services under the \"Qilu Insurance\" program, for the treatment of adult patients with type 2 diabetes. Clinical studies have shown that Esupaglutide Alpha, as a new-generation GLP-1 drug, demonstrates effective glucose-lowering results in the treatment of type 2 diabetes in adults. Additionally, positive data has been observed in weight-loss related clinical studies conducted in China and Australia. As a supplement to the flexible use of drugs listed in the National Reimbursement Drug List, this initiative represents the first and currently only practice in China combining a Class 1 GLP-1 innovative drug with commercial insurance online outpatient services. This move marks a significant step for INNOGEN in enhancing the accessibility of its innovative drug Yinuoqing® and supporting chronic disease management.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1147586009","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147586009","pubTimestamp":1775093921,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) rose more than 3% during morning trading. At the time of writing, the stock was up 2.94% to HK$22.22, with a turnover of HK$1.966 million. On April 1, INNOGEN announced via its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念"},"translate_title":"依苏帕鲁肽Alpha加入齐鲁保险名单，INNOGEN-B股价早盘上涨逾3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1,"VXUS":1},"content_text":"INNOGEN-B (02591) rose more than 3% during morning trading. At the time of writing, the stock was up 2.94% to HK$22.22, with a turnover of HK$1.966 million. On April 1, INNOGEN announced via its official social media account that Esupaglutide Alpha (Yinuoqing®) has been officially included in the specific drug list for online outpatient services under the \"Qilu Insurance\" program, for the treatment of adult patients with type 2 diabetes. Clinical studies have shown that Esupaglutide Alpha, as a new-generation GLP-1 drug, demonstrates effective glucose-lowering results in the treatment of type 2 diabetes in adults. Additionally, positive data has been observed in weight-loss related clinical studies conducted in China and Australia. As a supplement to the flexible use of drugs listed in the National Reimbursement Drug List, this initiative represents the first and currently only practice in China combining a Class 1 GLP-1 innovative drug with commercial insurance online outpatient services. This move marks a significant step for INNOGEN in enhancing the accessibility of its innovative drug Yinuoqing® and supporting chronic disease management.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147586009","isCrawlerRequest":true}